Lyell Immunopharma, Inc.LYELNASDAQ
LOADING
|||
Switch Symbol:
EBITDA Over Time
Trending higher, strong compound growth.
Left:
||||
Earnings before interest, taxes, depreciation, and amortization
Latest
$-200.64M
Near historical average
Average (5y)
$-185.64M
Historical baseline
Range
High:$-100.83M
Low:$-226.76M
CAGR
+14.8%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2024 | $-200.64M | +11.5% |
| 2023 | $-226.76M | -34.1% |
| 2022 | $-169.04M | +16.0% |
| 2021 | $-201.15M | +6.6% |
| 2020 | $-215.43M | -113.6% |
| 2019 | $-100.83M | - |